


Modified Form PTO-1449 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.	Serial No.
	A-579D	09/728,421
	Applicant Yoshinaga, et al	
	Filing Date November 28, 2000	Group

**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-	TRANSLATION

OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

C1	Attwood, T., "The Babel of Bioinformatics", <i>Science</i> , 290: 471-473, (20 Oct 2000).
C2	Blazar, et al., "Infusion of Anti-B7.1 (CD80) and Anti-B7.2 (CD86) Monoclonal Antibodies Inhibits Murine Graft-Versus-Host Disease Lethality In Part Via Direct Effects on CD4 ⁺ and CD8 ⁺ T Cells", <i>Jnl. of Immunol.</i> , 157: 3250-3259 (1996)
C3	Bowie et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions", <i>Science</i> , 247: 1306-1310, (16 March 1990).
C4	Dai, Z. et al., "The role of cytokines, CTLA-4 and costimulation in transplant tolerance and rejection", <i>Current Opinion in Immunology 1999 United Kingdom</i> , Vol. 11, No. 5, 504-508, (1999).
C5	Database UNIPROT [Online] Wang, et al.: "ICOS ligand precursor (B7 homolog 2) (B7-H2) (B7-like protein G150) (B7-related protein 1) (B7RP-1) (CD275 antigen)", UNIPROT Assession No. 075144, 15 July 1999.
C6	Database UNIPROT [Online] O'Regan, et al., "ICOS ligand.", UNIPROT Assession No. 042404, 1 January 1998.
C7	Fick, R. B., et al., "Immunotherapy approach to allergic disease", <i>Immunopharmacology</i> , 48: 307-310, (25 July 2000).
C8	Heaney, Liam G., et al., "Severe asthma treatment: need for characterising patients", <i>Lancet</i> , 365: 974-976, (12 March 2005).

EXAMINER: /Phillip Gambel/	Date Considered: 01/14/2011
----------------------------	-----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Modified Form PTO-1449 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.	A-579D	Serial No.	09/728,421
	Applicant	Yoshinaga, et al		
	Filing Date	November 28, 2000		
	Group			

OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

C9	Huang, Ziwei, "Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis", <i>Pharmacology & Therapeutics</i> , 86 : 201-215, (2000).
C10	Ishikawa, et al 'Prediction of the coding Sequences of Unidentified Human Genes. X. The Complete Sequences of 100 New cDNA Clones from Brain Which Can Code for Large Proteins <i>in vitro</i> ', <i>DNA Resh.</i> , 5 : 169-176 (1998)
C11	Kahan, Barry D., "Immunosuppressive therapy", <i>Current Opinion in Immunology</i> , 4 : 553-559, (1992).
C12	Metzler, et al., "Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28", <i>Nature Structural Biology</i> , 4 , No. 7: 527-531, (July 1997).
C13	The Merck Manual of Diagnosis and Therapy, Section 6 – Pulmonary Disorders, Chapter 68, Seventeenth Edition, Published by Merck Research Laboratories, Division of Merck & Co., Inc., Whitehouse Station, NJ, 556-557, (1999).
C14	Schultze, J., et al., "B7-mediated costimulation and the immune response", <i>Blood Reviews 1996 United Kingdom</i> , Vol. 10 , No. 2, 111-127, (1996).
C15	Skolnick, Jeffrey, et al., "From genes to protein structure and function: novel applications of computational approaches in the genomic era", <i>Trends in Biotechnology</i> , 18 (1): 34-39, (January 2000).

EXAMINER:	/Phillip Gambel/	Date Considered:	01/14/2011
<small>EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>			

2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./